CMRA | Comera Life Sciences Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0222 - 0.0222
52 Week Range	0.0212 - 0.4666
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	26,237
Average Volume	2,086
Shares Outstanding	30,737,800
Market Cap	682,379
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-21

Valuation
Profitability
Growth
Health
P/E Ratio	-0.10
Forward P/E Ratio	N/A
EPS	-0.22
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	12
Country	USA
Website	CMRA

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

CMRA's peers: ABIO, NTRB, BNOX, CADL, CING, EDSA, FBIOP, FBRX, GNLX, INDP, NNVC, PCSA, SABS, SYBX, TLSA, TPST, TTNP, MAIA, MLEC

*Chart delayed

Analyzing fundamentals for CMRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CMRA Fundamentals page.

Watching at CMRA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CMRA Technicals page.